Morgan Stanley
IMNM icon

Morgan Stanley’s Immunome IMNM Stock Holding History

Morgan Stanley’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.1M Buy
2,841,589
+1,132,500
+66% +$25.2M ﹤0.01% 1874
2025
Q4 		$36.7M Sell
1,709,089
-124,729
-7% -$2.19M ﹤0.01% 2381
2025
Q3 		$21.5M Buy
1,833,818
+1,429,461
+354% +$14.2M ﹤0.01% 2819
2025
Q2 		$3.76M Sell
404,357
-459,866
-53% -$3.77M ﹤0.01% 4289
2025
Q1 		$5.82M Buy
864,223
+465,356
+117% +$4.46M ﹤0.01% 3795
2024
Q4 		$4.24M Buy
398,867
+109,789
+38% +$1.33M ﹤0.01% 4137
2024
Q3 		$4.23M Sell
289,078
-82,880
-22% -$1.18M ﹤0.01% 4086
2024
Q2 		$4.5M Buy
371,958
+222,561
+149% +$3.48M ﹤0.01% 3978
2024
Q1 		$3.69M Buy
149,397
+125,087
+515% +$2.54M ﹤0.01% 4162
2023
Q4 		$260K Buy
24,310
+12,155
+100% +$101K ﹤0.01% 5847
2023
Q3 		$101K Sell
12,155
-1,311
-10% -$9.63K ﹤0.01% 5889
2023
Q2 		$107K Buy
13,466
+1,336
+11% +$7.31K ﹤0.01% 5926
2023
Q1 		$60.5K Hold
12,130
– – ﹤0.01% 6212
2022
Q4 		$26.8K Sell
12,130
-4
-0% -$16 ﹤0.01% 6552
2022
Q3 		$53K Sell
12,134
-796
-6% -$3.73K ﹤0.01% 6379
2022
Q2 		$41K Sell
12,930
-802
-6% -$2.92K ﹤0.01% 6692
2022
Q1 		$78K Sell
13,732
-64,983
-83% -$486K ﹤0.01% 6468
2021
Q4 		$1.02M Buy
78,715
+64,629
+459% +$1.15M ﹤0.01% 5055
2021
Q3 		$343K Buy
14,086
+2,715
+24% +$47.4K ﹤0.01% 5709
2021
Q2 		$196K Buy
11,371
+11,251
+9,376% +$249K ﹤0.01% 6026
2021
Q1 		$4K Sell
120
-2,128
-95% -$52.9K ﹤0.01% 7151
2020
Q4 		$22K Buy
+2,248
New +$26.2K ﹤0.01% 6404

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Morgan Stanley's IMNM Position: Q1 2026 in Review

Morgan Stanley increased its Immunome (IMNM) stake by 66% in Q1 2026, buying an estimated $25.2M and bringing the position to 2,841,589 shares worth $62.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

Morgan Stanley first reported a position in IMNM in Q4 2020 and has held it in 22 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Morgan Stanley held 2,841,589 shares of Immunome worth $62.1M as of Q1 2026.
  • Morgan Stanley bought 1,132,500 Immunome shares in Q1 2026, an estimated $25.2M.
  • Immunome made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1874 holding.
  • Morgan Stanley first reported a position in Immunome in Q4 2020 and has held it in 22 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.